Clinical Trials Browser

INDUSTRY × tremelimumab × 90 days × Clear all

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT06117891 2026-04-15

REFINE-IO

Recruiting

300 enrolled

Gastrointestinal

Unresectable Hepatocellular Carcinoma

NCT04960709 2026-04-14

VOLGA

Phase 3 Active not recruiting

712 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05301842 2026-04-07

EMERALD-3

Phase 3 Active not recruiting

760 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06008093 2026-03-30

TRITON

Phase 2 Active not recruiting

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03298451 2026-03-20

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Thoracic

Non Small Cell Lung Cancer NSCLC

NCT01843374 2026-03-05

Tremelimumab

Phase 2 Active not recruiting

571 enrolled 19 charts

Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05883644 2026-02-18

SIERRA

Phase 3 Active not recruiting

111 enrolled

Gastrointestinal

Liver Neoplasms

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02499328 2026-02-11

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Phase 1/2 Completed

340 enrolled 53 charts

Head & NeckOther solid neoplasm

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT03682068 2026-02-03

NILE

Phase 3 Active not recruiting

1,246 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3 Active not recruiting

1,126 enrolled 52 charts

Genitourinary

Urothelial Cancer

Clinical Trials

IMFINZI-subQ

REFINE-IO

VOLGA

EMERALD-3

TRITON

HIMALAYA

POSEIDON

Tremelimumab

MYSTIC

SIERRA

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

NILE

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer